What is Cerevance's official website?

Cerevance's website is cerevance.com

What is Cerevance's industry?

Cerevance's industry is Biotechnology Research

Who are Cerevance's top competitors?

Cerevance's top competitors are , , , , , ,

Cerevance company information, Employees & Contact Information

Explore related pages

Cerevance email format Cerevance management contacts

Related company profiles:

Cerevance

Employees: 53
Founded: -
Address: One Marina Park Drive, Suite 1410,united Kingdom
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: cerevance.com
Keywords: jobs.
HQ: Boston, MA
Competitors: Climb Bio, Carmot Therapeutics, Inc., Parabilis Medicines, Apnimed, Vertex Pharmaceuticals, Bioluminescence Ventures, Boundless Bio, Comanche Biopharma, Epicrispr Biotechnologies, Oculis.

Cerevance Questions

News

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Yahoo Finance

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 Yahoo Finance

Cerevance to Present Phase 2 Data on Solengepras in - GlobeNewswire

Cerevance to Present Phase 2 Data on Solengepras in GlobeNewswire

Cerevance Reports Positive Phase 1 Clinical Trial Results for KCNK13 Inhibitor and Upcoming Presentations at AAIC 2025 - Nasdaq

Cerevance Reports Positive Phase 1 Clinical Trial Results for KCNK13 Inhibitor and Upcoming Presentations at AAIC 2025 Nasdaq

Cerevance fails phase 2 trial in early, untreated Parkinson's - Fierce Biotech

Cerevance fails phase 2 trial in early, untreated Parkinson's Fierce Biotech

Cerevance Presents Topline Results from Phase 2 ASCEND - GlobeNewswire

Cerevance Presents Topline Results from Phase 2 ASCEND GlobeNewswire

Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback - Clinical Trials Arena

Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback Clinical Trials Arena

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists - ACS Publications

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists ACS Publications

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial - The Lancet

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial The Lancet

NETSseq's Impact On Cerevance's Approach to Drug Discovery - Pharmaceutical Executive

NETSseq's Impact On Cerevance's Approach to Drug Discovery Pharmaceutical Executive

Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - Pharma Voice

Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders Pharma Voice

A revival in neuro therapeutics - Fierce Pharma

A revival in neuro therapeutics Fierce Pharma

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor - ACS Publications

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor ACS Publications

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy - Clinical Trials Arena

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy Clinical Trials Arena

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline - GlobeNewswire

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline GlobeNewswire

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease - Yahoo Finance

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease Yahoo Finance

AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial - Clinical Trials Arena

AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial Clinical Trials Arena

Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023 - Clinical Trials Arena

Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023 Clinical Trials Arena

Parkinson Disease Agent CVN424 Shows Positive Results in Phase 2 Trial - NeurologyLive

Parkinson Disease Agent CVN424 Shows Positive Results in Phase 2 Trial NeurologyLive

Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras - Pharmaceutical Executive

Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras Pharmaceutical Executive

Cerevance Appoints Ottavio Vitolo, M.D., as Chief Medical Officer - citybiz

Cerevance Appoints Ottavio Vitolo, M.D., as Chief Medical Officer citybiz

Mixed results for Cerevance’s solengepras - The Pharma Letter

Mixed results for Cerevance’s solengepras The Pharma Letter

Cerevance's solengepras falls short in Phase II Parkinson's trial - FirstWord Pharma

Cerevance's solengepras falls short in Phase II Parkinson's trial FirstWord Pharma

Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck - The Wall Street Journal

Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck The Wall Street Journal

Merck forges Alzheimer’s pact with Cerevance - drugdiscoverytrends.com

Merck forges Alzheimer’s pact with Cerevance drugdiscoverytrends.com

Takeda taps brain-focused Cerevance in quest for new GI targets - Fierce Biotech

Takeda taps brain-focused Cerevance in quest for new GI targets Fierce Biotech

Merck & Co. partners with Cerevance in hunt for new Alzheimer's targets - FirstWord Pharma

Merck & Co. partners with Cerevance in hunt for new Alzheimer's targets FirstWord Pharma

It’s time to find new targets for brain diseases instead of just pursuing old ones - statnews.com

It’s time to find new targets for brain diseases instead of just pursuing old ones statnews.com

Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs - MedCity News

Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs MedCity News

Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE - Fierce Biotech

Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE Fierce Biotech

Leadership transition at Cerevance - The Pharma Letter

Leadership transition at Cerevance The Pharma Letter

Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact - BioSpace

Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact BioSpace

Cerevance - The Pharma Letter

Cerevance The Pharma Letter

Gates, GV chip into $45M round for CNS biotech Cerevance - Fierce Biotech

Gates, GV chip into $45M round for CNS biotech Cerevance Fierce Biotech

A biotech startup gives Merck its next shot at treating Alzheimer’s - BioPharma Dive

A biotech startup gives Merck its next shot at treating Alzheimer’s BioPharma Dive

Biotech Startup Cerevance Extends Series B to $65 Million - The Wall Street Journal

Biotech Startup Cerevance Extends Series B to $65 Million The Wall Street Journal

Positive results for Cerevance’s Parkinson’s drug - PharmaTimes

Positive results for Cerevance’s Parkinson’s drug PharmaTimes

Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster - BioSpace

Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster BioSpace

Companies like Cerevance

Top Cerevance Employees

Keith Page

n/a

Cambridge, England, United Kingdom, United Kingdom

View

2
asterand.com, cerevance.com
Marina Lizio

Principal Bioinformatician Cns And -Omics, Ml, Based In Cambridge, Uk.

United Kingdom, United Kingdom

View

2
cerevance.com, yahoo.it
Matthias Kleinz

Life Science Investor And Executive Vice President At Upmc Enterprises

Pittsburgh, Pennsylvania, United States, United States

View

5
novasenta.com, gmail.com, lek.com, upmc.edu, gmail.com

1 +141289XXXXX
Damon McCune, PhD, RDN, LD

Medical Affairs Leader Steering Business Excellence Through Innovation, Empowerment, And Strategy.

Dallas-Fort Worth Metroplex, United States, United States

View

3
yahoo.com, gmail.com, exactsciences.com

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Cerevance company information, Employees & Contact Information

Explore related pages

Company Details

Cerevance Questions

What is Cerevance's official website?

What is Cerevance's LinkedIn profile?

How many employees are working in Cerevance right now?

What is Cerevance's industry?

What are Cerevance's top competitors?

What are Cerevance's categories?

When was Cerevance founded?

News

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Yahoo Finance

Cerevance to Present Phase 2 Data on Solengepras in - GlobeNewswire

Cerevance Reports Positive Phase 1 Clinical Trial Results for KCNK13 Inhibitor and Upcoming Presentations at AAIC 2025 - Nasdaq

Cerevance fails phase 2 trial in early, untreated Parkinson's - Fierce Biotech

Cerevance Presents Topline Results from Phase 2 ASCEND - GlobeNewswire

Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback - Clinical Trials Arena

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists - ACS Publications

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial - The Lancet

NETSseq's Impact On Cerevance's Approach to Drug Discovery - Pharmaceutical Executive

Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - Pharma Voice

A revival in neuro therapeutics - Fierce Pharma

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor - ACS Publications

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy - Clinical Trials Arena

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline - GlobeNewswire

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease - Yahoo Finance

AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial - Clinical Trials Arena

Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023 - Clinical Trials Arena

Parkinson Disease Agent CVN424 Shows Positive Results in Phase 2 Trial - NeurologyLive

Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras - Pharmaceutical Executive

Cerevance Appoints Ottavio Vitolo, M.D., as Chief Medical Officer - citybiz

Mixed results for Cerevance’s solengepras - The Pharma Letter

Cerevance's solengepras falls short in Phase II Parkinson's trial - FirstWord Pharma

Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck - The Wall Street Journal

Merck forges Alzheimer’s pact with Cerevance - drugdiscoverytrends.com

Takeda taps brain-focused Cerevance in quest for new GI targets - Fierce Biotech

Merck & Co. partners with Cerevance in hunt for new Alzheimer's targets - FirstWord Pharma

It’s time to find new targets for brain diseases instead of just pursuing old ones - statnews.com

Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs - MedCity News

Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE - Fierce Biotech

Leadership transition at Cerevance - The Pharma Letter

Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact - BioSpace

Cerevance - The Pharma Letter

Gates, GV chip into $45M round for CNS biotech Cerevance - Fierce Biotech

A biotech startup gives Merck its next shot at treating Alzheimer’s - BioPharma Dive

Biotech Startup Cerevance Extends Series B to $65 Million - The Wall Street Journal

Positive results for Cerevance’s Parkinson’s drug - PharmaTimes

Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster - BioSpace

Companies like Cerevance

Carmot Therapeutics,...

Comanche Biopharma

Boundless Bio

Bioluminescence Vent...

Epicrispr Biotechnol...

Parabilis Medicines

Climb Bio

Oculis

Vertex Pharmaceuticals

Apnimed

Top Cerevance Employees

Keith Page

n/a

Marina Lizio

Principal Bioinformatician Cns And -Omics, Ml, Based In Cambridge, Uk.

Matthias Kleinz

Life Science Investor And Executive Vice President At Upmc Enterprises

Damon McCune, PhD, RDN, LD

Medical Affairs Leader Steering Business Excellence Through Innovation, Empowerment, And Strategy.

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data